Please use this identifier to cite or link to this item:
Title: Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models
Author: Guiteras, Jordi
Crespo Fernández, Elena
Fontova, Pere
Bolaños, Nuria
Gomà, Montse
Castaño, Esther
Bestard Matamoros, Oriol
Grinyo Boira, Josep M.
Torras Ambròs, Joan
Keywords: Lupus eritematós
Malalties autoimmunitàries
Malalties del ronyó
Lupus erythematosus
Autoimmune diseases
Kidney diseases
Issue Date: 29-Jul-2022
Publisher: MDPI AG
Abstract: Systemic lupus erythematosus is a complex autoimmune disorder mostly mediated by B-cells in which costimulatory signals are involved. This immune dysregulation can cause tissue damage and inflammation of the kidney, resulting in lupus nephritis and chronic renal failure. Given the previous experience reported with CTLA4-Ig as well as recent understanding of the PD-1 pathway in this setting, our group was encouraged to evaluate, in the NZBWF1 model, a human fusion recombinant protein (Hybri) with two domains: CTLA4, blocking the CD28-CD80 costimulatory pathway, and PD-L2, exacerbating the PD-1-PD-L2 coinhibitory pathway. After achieving good results in this model, we decided to validate the therapeutic effect of Hybri in the more severe MRL/lpr model of lupus nephritis. The intraperitoneal administration of Hybri prevented the progression of proteinuria and anti-dsDNA antibodies to levels like those of cyclophosphamide and reduced the histological score, infiltration of B-cells, T-cells, and macrophages and immune deposition in both lupus-prone models. Additionally, Hybri treatment produced changes in both inflammatory-related circulating cytokines and kidney gene expression. To summarize, both in vivo studies revealed that the Hybri effect on costimulatory-coinhibitory pathways may effectively mitigate lupus nephritis, with potential for use as a maintenance therapy.
Note: Reproducció del document publicat a:
It is part of: International Journal of Molecular Sciences, 2022, vol. 23, num. 15, p. 8411
Related resource:
ISSN: 1422-0067
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
ijms-23-08411-v2.pdf4.05 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons